Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects

Author(s): Saleh A. Alanazi*, Fars Alanazi, Nazrul Haq, Faiyaz Shakeel, Mohamed M. Badran, Gamaleldin I. Harisa

Journal Name: Current Drug Delivery

Volume 17 , Issue 10 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The prevalence of liver cancer is increasing over the years and it is the fifth leading cause of mortality worldwide. The intrusive features and burden of low survival rate make it a global health issue in both developing and developed countries. The recommended chemotherapy drugs for patients in the intermediate and advanced stages of various liver cancers yield a low response rate due to the nonspecific nature of drug delivery, thus warranting the search for new therapeutic strategies and potential drug delivery carriers. There are several new drug delivery methods available to ferry the targeted molecules to the specific biological environment. In recent years, the nano assembly of lipoprotein moieties (lipidic nanoparticles) has emerged as a promising and efficiently tailored drug delivery system in liver cancer treatment. This increased precision of nano lipoproteins conjugates in chemotherapeutic targeting offers new avenues for the treatment of liver cancer with high specificity and efficiency. This present review is focused on concisely outlining the knowledge of liver cancer diagnosis, existing treatment strategies, lipoproteins, their preparation, mechanism and their potential application in the treatment of liver cancer.

Keywords: Liver cancer, lipoproteins, LDL, HDL, receptor lipidic nanoparticle, ligand-target, drug delivery systems, anticancer drugs, therapeutic application.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 10
Year: 2020
Page: [826 - 844]
Pages: 19
DOI: 10.2174/1567201817666200206104338
Price: $65

Article Metrics

PDF: 7